<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:28:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9425145" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9425145</identifier>
        <datestamp>2022-09-16</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9425145</article-id>
              <article-id pub-id-type="pmcid">PMC9425145</article-id>
              <article-id pub-id-type="pmc-uid">9425145</article-id>
              <article-id pub-id-type="pmid">36036936</article-id>
              <article-id pub-id-type="pmid">36036936</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2022.29236</article-id>
              <article-id pub-id-type="publisher-id">zld220185</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Letter</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Infectious Diseases</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Remdesivir in Patients With Severe Kidney Dysfunction</article-title>
                <subtitle>A Secondary Analysis of the CATCO Randomized Trial</subtitle>
                <alt-title alt-title-type="headline">Remdesivir in Patients With Severe Kidney Dysfunction</alt-title>
                <alt-title alt-title-type="running-head">Remdesivir in Patients With Severe Kidney Dysfunction</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cheng</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>CM</degrees>
                  <xref rid="zld220185aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fowler</surname>
                    <given-names>Rob</given-names>
                  </name>
                  <degrees>MDCM</degrees>
                  <degrees>MS(Epi)</degrees>
                  <xref rid="zld220185aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Murthy</surname>
                    <given-names>Srinivas</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>CM</degrees>
                  <degrees>MHSc</degrees>
                  <xref rid="zld220185aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pinto</surname>
                    <given-names>Ruxandra</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zld220185aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sheehan</surname>
                    <given-names>Nancy L.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <degrees>MSc</degrees>
                  <xref rid="zld220185aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zld220185aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tseng</surname>
                    <given-names>Alice</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <xref rid="zld220185aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zld220185aff1"><label>1</label>McGill University Health Centre, Montréal, Québec, Canada</aff>
              <aff id="zld220185aff2"><label>2</label>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</aff>
              <aff id="zld220185aff3"><label>3</label>Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</aff>
              <aff id="zld220185aff4"><label>4</label>Faculty of Pharmacy, University of Montréal, Montréal, Québec, Canada</aff>
              <aff id="zld220185aff5"><label>5</label>University Health Network, Toronto General Hospital, Toronto, Ontario, Canada</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> July 13, 2022.</p>
                <p content-type="published-online"><bold>Published:</bold> August 29, 2022. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2022.29236</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2022 Cheng M et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zld220185cor1"><bold>Corresponding Author:</bold> Srinivas Murthy, MD, CM, MHSc, Faculty of Medicine, University of British Columbia, 4500 Oak St, Vancouver, BC, V6H 3V4 (<email xlink:href="srinivas.murthy@cw.bc.ca">srinivas.murthy@cw.bc.ca</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions</bold>: Drs Murthy and Pinto had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Cheng, Fowler, Murthy.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
                <p><italic>Drafting of the manuscript:</italic> Fowler, Murthy.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Cheng, Fowler, Pinto, Sheehan, Tseng.</p>
                <p><italic>Statistical analysis:</italic> Fowler, Murthy, Pinto.</p>
                <p><italic>Obtained funding:</italic> Cheng, Fowler, Murthy.</p>
                <p><italic>Administrative, technical, or material support:</italic> Cheng, Fowler.</p>
                <p><italic>Supervision:</italic> Fowler, Murthy.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Cheng reported receiving grants from the Canadian Institutes of Health Research and McGill Interdisciplinary Initiative in Infection and Immunity during the conduct of the study, fees (stock options) from GEn1E Lifesciences and Nomic Bio as a member of their scientific advisory boards, fees (equity) from Kanvas Biosciences as a cofounder of the company, consulting fees (honoraria) from Astra Zeneca, and research support from Cidara Therapeutics Scynexis Inc and Amplyx Pharmaceutics outside the submitted work. Dr Fowler reported receiving grants from the Canadian Institutes of Health Research during the conduct of the study. Dr Murthy reported receiving grants from Canadian Institutes of Health Research during the conduct of the study. Dr Sheehan reported receiving personal fees from Pfizer Canada, and personal fees from Merck Canada outside the submitted work. Dr Tseng reported personal consulting fees from Gilead Canada and personal fees from Pfizer Canada outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> Funding support was received from the Canadian Institutes of Health Research.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZLD220185-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2022-08-29T10:00">
                <day>29</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>5</volume>
              <issue>8</issue>
              <elocation-id>e2229236</elocation-id>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>5</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2022 Cheng M et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2229236.pdf">jamanetwopen-e2229236.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.29236"/>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZLD220185">
              <title>Introduction</title>
              <p>Remdesivir is a broad-spectrum antiviral that reduces hospitalization and may decrease mortality among noncritically ill inpatients with COVID-19.<sup><xref rid="zld220185r1" ref-type="bibr">1</xref>,<xref rid="zld220185r2" ref-type="bibr">2</xref></sup> Remdesivir is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min1.73 m<sup>2</sup> owing to the presence of excipients<sup><xref rid="zld220185r3" ref-type="bibr">3</xref></sup> that may accumulate in kidney dysfunction and worsen kidney or hepatic outcomes.<sup><xref rid="zld220185r4" ref-type="bibr">4</xref></sup></p>
              <p>The Canadian Treatments for COVID-19 (CATCO) trial randomized patients to remdesivir or standard care between August 1, 2020, and April 1, 2021, as part of the global Solidarity trial.<sup><xref rid="zld220185r5" ref-type="bibr">5</xref></sup> CATCO did not have kidney function–based exclusion criteria. We report on patients with impaired kidney function at baseline as a post hoc analysis to examine the risk of kidney or hepatic toxic effects with remdesivir administration.</p>
            </sec>
            <sec id="H1-2-ZLD220185">
              <title>Methods</title>
              <p>Details of CATCO are presented elsewhere.<sup><xref rid="zld220185r5" ref-type="bibr">5</xref></sup> This study was approved by all ethics committees and followed the <ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link> reporting guideline. Patients with impaired kidney function (eGFR &lt;30 mL/min/1.73 m<sup>2</sup> at randomization)<sup><xref rid="zld220185r6" ref-type="bibr">6</xref></sup> received open-label remdesivir or best-quality supportive care (eFigure in <xref rid="note-ZLD220185-1-s" ref-type="supplementary-material">Supplement 1</xref>). The trial protocol is available in <xref rid="note-ZLD220185-1-s" ref-type="supplementary-material">Supplement 2</xref>. Lyophilized remdesivir was diluted and administered intravenously with a loading dose of 200 mg on day 1, followed by daily 100-mg doses for 9 days or until discharge. There was no dose adjustment for baseline kidney dysfunction or dialysis. Adverse events were reported by clinical staff.</p>
              <p>We report all-cause mortality (unadjusted and adjusted for sex and baseline eGFR), adverse events, incidence of new ventilation or hemodialysis as proportions, and outcomes of day 5 eGFR and alanine aminotransferase levels, using medians (IQRs). There were no a priori levels of significance established. Given baseline imbalance, analysis of covariance was performed for the change in eGFR, adjusting for baseline eGFR. As sensitivity analysis, we report the results of binary outcomes for all patients in the main trial with eGFR 60 mL/min/1.73 m<sup>2</sup>, with 2-sided <italic>P</italic> values obtained through χ<sup>2</sup> tests. All analyses were performed in SAS, version 9.4 (SAS Institute Inc).</p>
            </sec>
            <sec id="H1-3-ZLD220185">
              <title>Results</title>
              <p>Of 1281 patients, 59 (remdesivir, 34; standard care, 25) had a baseline eGFR less than 30 mL/min/1.73 m<sup>2</sup>; median age was 74 (IQR, 63-86) years (<xref rid="zld220185t1" ref-type="table">Table 1</xref>). There were imbalances between the groups, with more men and a lower median eGFR at baseline in the standard-care group. At baseline, few patients were undergoing hemodialysis; median eGFR was 18.9 (IQR, 10.2-24.2) mL/min/1.73 m<sup>2</sup> across groups.</p>
              <table-wrap position="float" id="zld220185t1">
                <label>Table 1. </label>
                <caption>
                  <title>Baseline Characteristics of Randomized Patients With eGFR Less Than 30 mL/min/1.73 m<sup>2</sup> at Time of Randomization</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="42.05%" span="1"/>
                  <col width="16.42%" span="1"/>
                  <col width="19.53%" span="1"/>
                  <col width="22%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Variable<xref rid="zld220185t1n1" ref-type="table-fn"><sup>a</sup></xref></th>
                      <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Overall (N = 59)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Remdesivir (n = 34)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard care (n = 25)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, median (IQR), y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">74 (63-86)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">74 (66-86)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">80 (63-85)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex at birth</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">29 (49.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">21 (61.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8 (32.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30 (50.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">13 (38.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17 (68.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Clinical frailty score, median (IQR)<xref rid="zld220185t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5 (4-6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4 (3-6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5 (4-6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline severity</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> In ICU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">18 (30.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">11 (32.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">7 (28.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No oxygen</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4 (6.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4 (11.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Receiving oxygen</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30 (50.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16 (47.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14 (56.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High-flow nasal cannulae</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14 (23.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (17.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8 (32.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Noninvasive ventilation</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2 (3.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1 (2.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1 (4.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Invasive ventilation</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9 (15.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">7 (20.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2 (8.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline creatinine, median (IQR), mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.97 (2.22-5.54)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.62 (2.02-5.17)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3.88 (2.65-6.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline eGFR, median (IQR), mL/min/1.73 m<sup>2</sup></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">18.9 (10.2-24.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">22.7 (10.5-26.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">12.4 (8.8-20.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline need for dialysis</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15 (25.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9 (26.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (24.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline ALT, median (IQR), U/L<xref rid="zld220185t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">28 (21-45)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">27 (21-49)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">35 (21-43)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; ICU, intensive care unit.</p>
                  <p>SI conversion: To convert ALT to microkatals per liter, multiply by 0.0167; creatinine to micromoles per liter, 88.4.</p>
                  <fn id="zld220185t1n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Data on race and ethnicity were collected but are not reported owing to the small numbers.</p>
                  </fn>
                  <fn id="zld220185t1n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Clinical Frailty score is a 9-point scoring system, with lower scores indicating a lower level of frailty.</p>
                  </fn>
                  <fn id="zld220185t1n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Available in 39 patients.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The median duration of remdesivir administered in the intervention arm was 10 (IQR, 6-10) days (mean, 8.2 days). There were no significant differences in key outcomes between groups (<xref rid="zld220185t2" ref-type="table">Table 2</xref>). Adjustment for sex and baseline eGFR did not change mortality outcomes (odds ratio, 0.74; 95% CI, 0.23-2.40). Analysis of covariance for change in eGFR showed no significant difference between groups. For patients with eGFR less than 60 mL/min/1.73 m<sup>2</sup> (n = 248) at randomization, there was no significant difference between those receiving remdesivir (n = 122) or standard care (n = 126) in hospital mortality (35.2% vs 42.1%; <italic>P</italic> = .26), new mechanical ventilation (10.6% vs 15.7%; <italic>P</italic> = .27), or new dialysis (6.2% vs 5.0%; <italic>P</italic> = .70).</p>
              <table-wrap position="float" id="zld220185t2">
                <label>Table 2. </label>
                <caption>
                  <title>Clinical Outcomes of Patients With eGFR Less Than 30 mL/min/1.73 m<sup>2</sup> at Time of Randomization<xref rid="zld220185t2n1" ref-type="table-fn"><sup>a</sup></xref></title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="45.56%" span="1"/>
                  <col width="14.5%" span="1"/>
                  <col width="16.34%" span="1"/>
                  <col width="23.6%" span="1"/>
                  <thead>
                    <tr>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Variable</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Remdesivir (n = 34)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard care (n = 25)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Difference in means (95% CI)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hospital death, No. (%), unadjusted</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">13 (40.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">13 (52.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">RR, 0.78 (0.41 to 1.49)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">New mechanical ventilation in those not ventilated at baseline, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4 (14.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (26.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">RR, 0.57 (0.15 to 1.80)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Total length of stay, d</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">23.1 (20.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">21.6 (28.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.5 (–11.5 to 14.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16.5 (10-29.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">11 (6-25)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 5 creatinine, mg/dL<xref rid="zld220185t2n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.83 (2.15)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.12 (2.41)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">–1.29 (–2.66 to 0.09)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.80 (1.32-3.40)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3.47 (2.02-5.99)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 5 eGFR, mL/min/1.73 m<sup>2</sup><xref rid="zld220185t2n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">31.2 (19.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">20.5 (13.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.7 (0.20 to 21.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">29.2 (14.2-45)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16.5 (8.5-30.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">ANCOVA for change in eGFR</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1">–0.26 (–7.95 to 7.42)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Day 5 ALT<xref rid="zld220185t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">40.8 (36.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">91.9 (187)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">–51.1 (–177.2 to 75.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">32.5 (15-47)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">31 (22-52)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">New dialysis in those not receiving dialysis at baseline, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5 (20.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4 (21.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">RR, 0.95 (0.25 to 3.56)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any adverse event, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3 (8.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (24.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">RR, 0.37 (0.05 to 1.33)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: ALT, alanine aminotransferase; ANCOVA, analysis of covariance; eGFR, estimated glomerular filtration rate; NA, not applicable; RR, relative risk.</p>
                  <p>SI conversion: To convert ALT to microkatals per liter, multiply by 0.0167; creatinine to micromoles per liter, 88.4.</p>
                  <fn id="zld220185t2n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Percentages reported for those with available outcome.</p>
                  </fn>
                  <fn id="zld220185t2n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Available in 45 patients.</p>
                  </fn>
                  <fn id="zld220185t2n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Available in 31 patients.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec id="H1-4-ZLD220185">
              <title>Discussion</title>
              <p>In patients with eGFR less than 30 mL/min/1.73 m<sup>2</sup> at baseline who received remdesivir, there was no increased risk of transaminitis or toxic kidney effects at day 5. There was also no significant difference in the need for invasive mechanical ventilation or new dialysis, or mortality. This study is limited by small numbers and baseline imbalance between groups. These findings suggest that remdesivir can be safely administered in patients with kidney dysfunction, balancing possible risks and benefits. The need for assessing kidney function in the absence of clinical suspicion before and during outpatient administration of remdesivir can be questioned.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZLD220185">
              <title>References</title>
              <ref id="zld220185r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gottlieb</surname><given-names>RL</given-names></string-name>, <string-name><surname>Vaca</surname><given-names>CE</given-names></string-name>, <string-name><surname>Paredes</surname><given-names>R</given-names></string-name>, <etal/>; <collab>GS-US-540-9012 (PINETREE) Investigators</collab></person-group>. <article-title>Early remdesivir to prevent progression to severe Covid-19 in outpatients</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>386</volume>(<issue>4</issue>):<fpage>305</fpage>-<lpage>315</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2116846</pub-id><?supplied-pmid 34937145?><pub-id pub-id-type="pmid">34937145</pub-id></mixed-citation>
              </ref>
              <ref id="zld220185r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><collab>WHO Solidarity Trial Consortium</collab></person-group>. <article-title>Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses</article-title>. <source>Lancet</source>. <year>2022</year>;<volume>399</volume>(<issue>10339</issue>):<fpage>1941</fpage>-<lpage>1953</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(22)00519-0</pub-id><?supplied-pmid 35512728?><pub-id pub-id-type="pmid">35512728</pub-id></mixed-citation>
              </ref>
              <ref id="zld220185r3">
                <label>3</label>
                <mixed-citation publication-type="other">Remdesivir. Package insert. Gilead Sciences Inc; <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="zld220185r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Luke</surname><given-names>DR</given-names></string-name>, <string-name><surname>Tomaszewski</surname><given-names>K</given-names></string-name>, <string-name><surname>Damle</surname><given-names>B</given-names></string-name>, <string-name><surname>Schlamm</surname><given-names>HT</given-names></string-name></person-group>. <article-title>Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)</article-title>. <source>J Pharm Sci</source>. <year>2010</year>;<volume>99</volume>(<issue>8</issue>):<fpage>3291</fpage>-<lpage>3301</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jps.22109</pub-id><?supplied-pmid 20213839?><pub-id pub-id-type="pmid">20213839</pub-id></mixed-citation>
              </ref>
              <ref id="zld220185r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ali</surname><given-names>K</given-names></string-name>, <string-name><surname>Azher</surname><given-names>T</given-names></string-name>, <string-name><surname>Baqi</surname><given-names>M</given-names></string-name>, <etal/>; <collab>Canadian Treatments for COVID-19 (CATCO)</collab>; <collab>Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group</collab></person-group>. <article-title>Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial</article-title>. <source>CMAJ</source>. <year>2022</year>;<volume>194</volume>(<issue>7</issue>):<fpage>E242</fpage>-<lpage>E251</lpage>. doi:<pub-id pub-id-type="doi">10.1503/cmaj.211698</pub-id><?supplied-pmid 35045989?><pub-id pub-id-type="pmid">35045989</pub-id></mixed-citation>
              </ref>
              <ref id="zld220185r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Levey</surname><given-names>AS</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>LA</given-names></string-name></person-group>. <article-title>Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions</article-title>. <source>Am J Kidney Dis</source>. <year>2010</year>;<volume>55</volume>(<issue>4</issue>):<fpage>622</fpage>-<lpage>627</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2010.02.337</pub-id><?supplied-pmid 20338463?><pub-id pub-id-type="pmid">20338463</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZLD220185-1">
              <supplementary-material id="note-ZLD220185-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p><bold>eFigure.</bold> Randomization of Participants</p>
                </caption>
                <media xlink:href="jamanetwopen-e2229236-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2229236-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2229236-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
